Friday, June 5, 2026

North Korea’s New Missiles Could Reach South Korea’s Heartland—Here’s the Latest Intel

South Korea's NIS revealed North Korea's new short-range ballistic missiles (SRBMs) have a 610 km range, reaching Chungcheong Province.

Seoul Marginalized? Trump’s Key Focus At Korea-Hosted APEC Is A China Summit

U.S. and South Korea reaffirm commitment to North Korea's denuclearization and strengthen bilateral ties during a UN meeting.

Korea’s Chip Giants, Samsung and SK Hynix, Caught Between U.S. Tariff Ultimatum and Domestic Relocation Debate

Samsung and SK Hynix face challenges amid U.S. tariffs and local relocation debates, risking their semiconductor supercycle potential.

Lunit supplies integrated breast cancer diagnostic solution to Lexington Clinic

HealthLunit supplies integrated breast cancer diagnostic solution to Lexington Clinic
Courtesy of Lunit
Courtesy of Lunit

Medical artificial intelligence (AI) company Lunit said on the 17th it has supplied an integrated breast cancer AI diagnostic solution to Lexington Clinic in the United States.

Lexington Clinic has established an AI-based breast cancer diagnostic system by adopting Lunit’s mammography AI image analysis solution, “Lunit INSIGHT MMG,” and its 3D breast imaging AI solution, “Lunit INSIGHT DBT.”

The clinic also introduced solutions from Lunit International (formerly Volpara), covering image quality optimization, breast density assessment and patient tracking management, enabling the entire breast cancer diagnostic process to be operated on Lunit’s platform.

The adoption by Lexington Clinic symbolically demonstrates Lunit’s business expansion in the Americas.

Following this supply agreement, about one year after integrating the products of Lunit and Lunit International, the company has supplied integrated solutions to more than 330 medical institutions across the Americas, supporting approximately 1 million mammography screenings annually.

As it enters a phase of expansion in the United States market, Lunit is focusing on product advancement. Recently, the company received marketing authorization from the U.S. Food and Drug Administration (FDA) for an upgraded version of Lunit INSIGHT DBT.

The upgraded product includes features that compare current and prior examinations and allows adjustment of sensitivity and specificity based on screening environments, enhancing its usability in clinical settings.

CEO Suh Beom-seok said, “Supplying an integrated solution covering the entire breast cancer screening process to a major healthcare group in the United States and expanding our business to more than 330 institutions across the Americas reflects the combined strength of Lunit’s AI technology and Lunit International’s market capabilities,” adding, “We will continue to expand our presence in the global breast cancer screening market beyond the Americas.”

Meanwhile, Lunit is currently participating in the “2026 Society of Breast Imaging (SBI)” being held in Seattle, United States.

Check Out Our Content

Check Out Other Tags:

Most Popular Articles